News
Variational AI Named “Gamechanger – AI” at BC Tech’s 2026 Technology Impact Awards
Variational AI is proud to announce that it has been named the winner of the Gamechanger – AI award at the BC Tech Association’s 2026 Technology Impact Awards (TIAs) Read More about Variational AI Named “Gamechanger – AI” at BC Tech’s 2026 Technology Impact Awards
Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US$1 million
How Rakovina Therapeutics designed a novel, brain-penetrant ATR inhibitor with Enki™: one design cycle to four IP-clear lead series, five optimization cycles to sub-nanomolar potency, 122 compounds, about two years,… Read More about Case study | A brain-penetrant ATR inhibitor, candidate-ready in two years for US class=”wp-block-post-excerpt__more-link” href=”https://variational.ai/news/use-case/case-study-brain-penetrant-atr-inhibitor-kt-5000/” million
SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
Variational AI has entered a research collaboration with SK Life Science Labs, the U.S. discovery research subsidiary of SK Biopharmaceuticals. Variational AI will use its Enki™ generative AI platform to… Read More about SK Life Science Labs Selects Variational AI’s Enki™ Platform for Generative AI-Driven Lead Discovery
3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Vancouver-based 3C Therapeutics to apply Variational AI’s Enki™ platform to ligand design for proprietary TriCore DAC platform under Innovate BC’s Integrated Marketplace program Read More about 3C Therapeutics and Variational AI Launch Generative AI Collaboration to Design Next-Generation Degrader Antibody Conjugates, Supported by Innovate BC
Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Variational AI introduces Enki™ 4: an improved algorithm and architecture designed to scale, expanding the pre-trained target coverage from 592 to 760 and now applicable to proximity-based therapeutics and novel… Read More about Variational AI releases Enki 4: Major update to foundation model for small- molecule drug discovery
Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI is pleased to share that Enamine has joined the Agora Open Science Trust collaboration focused on discovering novel PRMT6 inhibitors for Spinal and Bulbar Muscular Atrophy (SBMA), a… Read More about Enamine joins Variational AI in Agora Open-Science PRMT6 Discovery Effort
Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Variational AI and Rakovina Therapeutics expand their collaboration to advance Rakovina’s kt-5000 series of ATR inhibitors Read More about Variational AI and Rakovina Therapeutics Expand Collaboration to Accelerate Next-Generation ATR Inhibitors
Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Building on their initial hit series, Variational AI and Rakovina Therapeutics share promising new results on ATR inhibitors generated with Enki. The latest findings reveal compounds that balance potency, selectivity,… Read More about Update: Advancing CNS-penetrant ATR inhibitors with Enki™
Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
Variational AI, a generative AI drug discovery company, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to… Read More about Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery
